二甲双胍抑制赖氨酸特异性组蛋白去甲基化酶1介导的卵巢癌细胞增殖和迁移

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (16607 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the molecular mechanism of metformin in inhibiting the proliferation and migration of ovarian cancer cells. Methods: Ovarian cancer HO8910 and SKOV3 cells were treated with metformin at different concentrations(0, 5, 10, and 20 mmol/L), cell proliferation and migration ability were measured by EdU and migration assays, lysine specific demethylase 1(LSD1) protein and mRNA expression levels were detected by Western blotting and qRTPCR, the protein expression level of PI3K/AKT signaling pathway was detected by Western blotting. In addition, inducible stable knockdown of LSD1 ovarian cancer HO8910 and SKOV3 cell lines were established, and the effects of metformin treatment and LSD1 knockdown on the proliferation and migration of ovarian cancer cells were measured by EdU and migration assays. Results: Compared with the control group, the cell proliferation and migration ability of the metformin treatment groups were significantly reduced(all P<0.01). The expression level of LSD1 protein was significantly reduced, and the protein level of H3K4me2, a specific substrate of LSD1, was significantly increased (all P<0.01). The protein expression levels of PI3K and pAKT in PI3K/AKT signaling pathway were significantly reduced (all P<0.01). After metformin treatment and LSD1 knockdown, the cell proliferation and migration ability were significantly reduced(P<0.05）. Conclusion: Metformin may inhibit the proliferation and migration of ovarian cancer cells by downregulating LSD1 protein expression via inhibiting the PI3K/AKT pathway.

Received: 27 December 2019

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HAN Tian-tian
	MENG Hong-xia
	ZHAO Kang-rong
	SUN Ai-qin
	YANG Wan-nian
	SHAO Gen-bao

Cite this article:

HAN Tian-tian,MENG Hong-xia,ZHAO Kang-rong等.

Metformin inhibits LSD1-mediated proliferation and migration of ovarian cancer cells

[J]. Journal of Jiangsu University(Medicine Edition), 2020, 30(02): 131-137.

URL:

http://zzs.ujs.edu.cn/xbyxb/EN/ OR http://zzs.ujs.edu.cn/xbyxb/EN/Y2020/V30/I02/131

［1］Maruthur NM, Tseng E, Hutfless S, et al. Diabetes medications as monotherapy or metforminbased combination therapy for type 2 diabetes: a systematic review and metaanalysis\[J\]. Ann Intern Med, 2016, 164(11): 740-751.

［2］Podhorecka M, Ibanez B, Dmoszynska A. Metforminits potential anticancer and antiaging effects\[J\]. Postepy Hig Med Dosw (Online), 2017, 70(3): 170-175.

［3］Rattan R, Graham RP, Maguire JL, et al. Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo\[J\]. Neoplasia, 2011, 13(5): 483-491.

［4］Lan F, Nottke AC, Shi Y. Mechanisms involved in the regulation of histone lysine demethylases\[J\]. Curr Opin Cell Biol, 2008, 20(3): 316-325.

［5］Konovalov S, GarciaBassets I. Analysis of the levels of lysinespecific demethylase 1(LSD1) mRNA in human ovarian tumors and the effects of chemical LSD1 inhibitors in ovarian cancer cell lines\[J\]. J Ovarian Res, 2013, 6(1): 75.

［6］Lv T, Yuan D, Miao X, et al. Overexpression of LSD1 promotes proliferation, migration and invasion in nonsmall cell lung cancer\[J\]. PLoS One, 2012, 7(4): e35065.

［7］Lim S, Janzer A, Becker A, et al. Lysinespecific demethylase 1 (LSD1) is highly expressed in ERnegative breast cancers and a biomarker predicting aggressive biology\[J\]. Carcinogenesis, 2010, 31(3): 512-520.

［8］Zhang J, Zhao D, Li Q, et al. Upregulation of LSD1 promotes migration and invasion in gastric cancer through facilitating EMT\[J\]. Cancer Manag Res, 2019, 21: 4481-4491.

［9］Chen C, Ge J, Lu Q, et al. Expression of Lysinespecific demethylase 1 in human epithelial ovarian cancer\[J\]. J Ovarian Res, 2015, 8: 28.

［10］Fu X, Zhang P, Yu B, et al. Advances toward LSD1 inhibitors for cancer therapy\[J\]. Future Med Chem, 2017, 9(11): 1227-1242.

［11］Wei Y, Han T, Wang R, et al. LSD1 negatively regulates autophagy through the mTOR signaling pathway in ovarian cancer cells\[J\]. Oncol Rep, 2018, 40(1): 425-433.

［12］Coburn SB, Bray F, Sherman ME, et al. International patterns and trends in ovarian cancer incidence, overall and by histologic subtype\[J\]. Int J Cancer, 2017, 140(11): 2451-2460.

［13］Lengyel E, Litchfield LM, Mitra AK, et al. Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models\[J\]. Am J Obstet Gynecol, 2015, 212(4): 479.e1-479.e10.

［14］Rattan R, Giri S, Hartmann LC, et al. Metformin attenuates ovarian cancer cell growth in an AMpkinase dispensable manner\[J\]. J Cell Mol Med, 2019, 15(1): 166-178.

［15］Liu Y, Zhang Y, Jia K, et al. Metformin inhibits the proliferation of A431 cells by modulating the PI3K/Akt signaling pathway\[J\]. Exp Ther Med, 2015, 9(4): 1401-1406.

［16］Shao G, Wang J, Li Y, et al. Lysinespecific demethylase 1 mediates epidermal growth factor signaling to promote cell migration in ovarian cancer cells\[J\]. Sci Rep, 2015, 5: 15344.

［17］Li Y, Wan X, Wei Y, et al. LSD1mediated epigenetic modification contributes to ovarian cancer cell migration and invasion\[J\]. Oncol Rep, 2016, 35(6): 3586-3592.